HilleVax, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLVX research report →
Range $30 – $34
Price Chart
About the company
HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections.
- CEO
- Robert M. Hershberg
- IPO
- 2022
- Employees
- 14
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on HLVX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $104.76M
- P/E
- -9.09
- Fwd P/E
- 104.50
- PEG
- -0.10
- P/S
- 0.00
- P/B
- 0.71
- EV/EBITDA
- -6.72
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -7.58%
- ROIC
- -8.46%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-155,291,000
- Net Income
- $-147,267,000-19.2%
- EPS
- $-3.00+1.3%
- OCF Growth
- -25.4%
- FCF Growth
- -12.1%
- 52W High
- $2.17
- 52W Low
- $1.34
- 50D MA
- $2.09
- 200D MA
- $1.92
- Beta
- 0.77
- RSI (14)
- 51
- Avg Volume
- 718.71K
No earnings-call transcripts are available for HLVX yet.
- Free Float
- 45.4%
- Shares Outstanding
- 50.13M
- Float Shares
- 22.74M
of shares held by institutions
81 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock Inc. | 2.09M | ▲ 290.33K |
| Credit Suisse AG/ | 15.69K | ▲ 3.83K |
Held by 4 ETFs
Biggest fund positions in HLVX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 17, 25 | TAKEDA PHARMACEUTICAL CO LTD | other | 6,724,000 |
| Sep 17, 25 | Frazier Life Sciences X, L.P. | other | 17,199 |
| Sep 17, 25 | HERSHBERG ROBERT | other | 1,101,498 |
| Sep 17, 25 | Cocero Nanette | other | 17,199 |
| Sep 17, 25 | HILLEMAN JERYL L | other | 59,224 |
| Sep 17, 25 | Chu Shelley | other | 17,199 |
| Sep 17, 25 | Dubin Gary | other | 17,199 |
| Sep 17, 25 | Kohli Aditya | other | 698,171 |
| Sep 17, 25 | Gerberding Julie L. | other | 59,224 |
| Sep 17, 25 | Maltbie Shane | other | 83,738 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our HLVX coverage
Recent articles, reports, and earnings notes.
No research on HLVX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HLVX report →HILLEVAX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX
globenewswire.com · Aug 19
Shareholder Alert: The Ademi Firm Investigates Whether HilleVax, Inc. Is Obtaining a Fair Price for Its Public Shareholders
businesswire.com · Aug 8
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of HilleVax, Inc. (NASDAQ: HLVX)
prnewswire.com · Aug 7
HilleVax Reports Second Quarter 2025 Financial Results
globenewswire.com · Aug 6
HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc. - HLVX
businesswire.com · Aug 5
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HilleVax, Inc.
prnewswire.com · Aug 5
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: HilleVax, Inc. (Nasdaq – HLVX), Steelcase Inc. (NYSE – SCS), LAVA Therapeutics N.V. (Nasdaq – LVTX), Arcadia Biosciences, Inc. (Nasdaq – RKDA)
globenewswire.com · Aug 4
Shareholder Alert: The Ademi Firm investigates whether HilleVax, Inc. is obtaining a Fair Price for its Public Shareholders
prnewswire.com · Aug 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.